Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Executive Summary

Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.


Related Content

Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III
Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
Gilead Pays Phenex $100m Milestone As NASH Candidate Progresses
Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts